Calviri Diagnostic Pipeline
Calviri is actively driving forward an integrated Pipeline of Cancer Diagnostic Tests.
A prognostic test is in development to identify patients who will clinically respond positively to immune checkpoint inhibitors, and those that will experience adverse events has been demonstrated (Shen et.al. J Transl Med, 2023).
A stage 1 diagnostic test for the most common cancers in humans is proceeding through feasibility studies. Development plans are in place.
A stage 1 diagnostic test for the most common cancers in dogs is proceeding through feasibility studies. Development plans are in place.